Opendata, web and dolomites

AURORAX SIGNED

Advancing cancer detection through metabolism-based diagnostics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AURORAX project word cloud

Explore the words cloud of the AURORAX project. It provides you a very rough idea of what is the project "AURORAX" about.

clearance    ups    clinical    stages    terminal    biopsy    exceptional    generate    cancer    elypta    introduce    metabolism    benefit    urologists    demonstrated    significantly    detected    ruo    imaging    regulatory    aur87    signed    diagnosed    risks    multiple    niche    launch    starting    carcinoma    surgery    first    strategy    stage    200b    validation    basis    ing    annual    20    optimize    rcc    letter    frequent    trials    companies    former    urine    metastatic    patient    recurrences    detect    enter    platform    laboratories    12    rates    competition    signature    solid    outcomes    expressing    liquid    quantification    follow    trial    letters    algorithmic    survival    effectiveness    too    independent    small    sales    recurrence    139    cell    obtain    oncologist    surveil    risk    once    improves    off    regular    business    diagnostics    radiation    market    indications    financially    easily    treatment    receive    pharmaceutical    disease    patients    sweden    frequency    monitoring    blood    aurorax    perform    drop    scalable    limited    renal    sensitivity    metabolite   

Project "AURORAX" data sheet

The following table provides information about the project.

Coordinator
ELYPTA AB 

Organization address
address: REGERINGSGATAN 65, 3TR
city: STOCKHOLM
postcode: 111 56
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 3˙346˙674 €
 EC max contribution 2˙342˙671 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2021-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ELYPTA AB SE (STOCKHOLM) coordinator 2˙342˙671.00

Map

 Project objective

Former cancer patients receive regular follow-ups to detect recurrences at early stages and optimize treatment outcomes. The follow-up frequency is currently limited by costs and radiation risks of imaging approaches used to surveil for recurrences, resulting in recurrences being detected too late – often resulting in terminal disease. Of the 139.000 annual Renal Cell Carcinoma (RCC) patients, 20% are diagnosed with a metastatic recurrence within 5 years after surgery. Once metastatic, RCC survival rates drop to 12% over 5 years survival. Elypta, Sweden, has developed the first metabolism-based liquid biopsy to detect early-stage recurrences. The quantification of a metabolite signature in blood or urine and an algorithmic analysis allows for exceptional sensitivity, a low cost of the platform and significantly improves on imaging approaches in cost and risk, enabling frequent patient follow-up. Elypta’s technology has been demonstrated in small clinical trials and its cost effectiveness assessed by two independent companies. Elypta’s platform is easily scalable to other cancer indications and applications such as treatment monitoring, as demonstrated in multiple small trials. Starting in the niche RCC market with limited competition, Elypta now requires clinical evidence for a product launch within RCC. The business strategy focuses on distribution and sales through clinical laboratories, which will benefit financially off sales. During the AURORAX, Elypta will 1) perform a clinical validation trial (AUR87) to generate strong clinical evidence, 2) obtain regulatory clearance in the EU and the US and 3) introduce the product for research use only (RUO) and after clinical validation enter the RCC diagnostics market in EU. As users of the platform, oncologist and urologists have all signed letters of support. A pharmaceutical partner has also signed a letter of support, expressing their interest in RUO use of the platform, providing a solid basis in the emerging liquid biopsy market (€200B market).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AURORAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AURORAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More